中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

文献类型：期刊论文

作者Wei, Qing12,13,14; Li, Peijing11,13; Yang, Teng10,13; Zhu, Jiayu9; Sun, Lu8,13; Zhang, Ziwen13,14; Wang, Lu7; Tian, Xuefei5,6,13; Chen, Jiahui1,12,13; Hu, Can1,12,13
刊名JOURNAL OF HEMATOLOGY & ONCOLOGY
出版日期2024-01-04
卷号17期号:1页码:32
关键词Antibody-drug conjugate Solid tumor Combination therapy Immunotherapy Targeted therapy
DOI10.1186/s13045-023-01509-2
通讯作者Ying, Jieer(jieerying@aliyun.com) ; Guo, Peng(guopeng@ucas.ac.cn) ; Cheng, Xiangdong(chengxd@zjcc.org.cn)
英文摘要Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.
WOS关键词TRASTUZUMAB EMTANSINE T-DM1 ; METASTATIC BREAST-CANCER ; PLUS PEMBROLIZUMAB PEMBRO ; DNA-DAMAGE RESPONSE ; DERUXTECAN T-DXD ; MIRVETUXIMAB SORAVTANSINE ; PATIENTS PTS ; SACITUZUMAB GOVITECAN ; PLATINUM CHEMOTHERAPY ; INELIGIBLE PATIENTS
资助项目National Natural Science Foundation of China
WOS研究方向Oncology ; Hematology
语种英语
WOS记录号WOS:001136485900001
出版者BMC
源URL[http://119.78.100.183/handle/2S10ELR8/308760]  
专题中国科学院上海药物研究所
通讯作者Ying, Jieer; Guo, Peng; Cheng, Xiangdong
作者单位1.Zhejiang Canc Hosp, Dept Gastr Surg, Hangzhou, Peoples R China
2.Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
3.Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Japan
4.Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
5.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Coll Mol Med, Hangzhou, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
7.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
8.Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China
9.Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
10.Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714		 Wei, Qing,Li, Peijing,Yang, Teng,et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2024,17(1):32.
APA Wei, Qing.,Li, Peijing.,Yang, Teng.,Zhu, Jiayu.,Sun, Lu.,...&Cheng, Xiangdong.(2024).The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.JOURNAL OF HEMATOLOGY & ONCOLOGY,17(1),32.
MLA Wei, Qing,et al."The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors".JOURNAL OF HEMATOLOGY & ONCOLOGY 17.1(2024):32.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。